Register of
Medicinal Products

Product class: Medicinal product with marketing authorization
Medicinal product class: Veterinary medicine
Name of medicinal product: Advantix
Active substances:
Estonian, English, Latin
ATC code: QP53AC88
Dosage form: spot-on solution
Strength: 200mg+40mg 0.4ml
Legal status for supply*: Not subject to medicinal prescription
Summary of product characteristics (SPC):  (last updated March 4, 2024)
Package information leaflet (PIL): EST  (last updated March 4, 2024)
Labelling:  (last updated March 4, 2024)
Indication: For the treatment and prevention of flea (Ctenocephalides canis, Ctenocephalides felis) infestation. Fleas on dogs are killed within one day following treatment. One treatment prevents further flea infestation for four weeks. The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD). For the treatment of biting lice (Trichodectes canis). The product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for four weeks, and Dermacentor reticulatus for three weeks). By repelling and killing the tick vector Rhipicephalus sanguineus, the product reduces the likelihood of transmission of the pathogen Ehrlichia canis, thereby reducing the risk of canine ehrlichiosis. The reduction in risk has been shown in studies to commence from 3 days following application of the product and to persist for 4 weeks. Ticks already on the dog may not be killed within two days after treatment and may remain attached and visible. Therefore the removal of ticks already on the dog at the time of treatment is recommended, in order to prevent them from attaching and having a blood meal. One treatment provides repellent (anti-feeding) activity against sand flies (Phlebotomus papatasi for two weeks and Phlebotomus perniciosus for three weeks), against mosquitoes (Aedes aegypti for two weeks and Culex pipiens for four weeks) and against stable flies (Stomoxys calcitrans) for four weeks. Reduction of the risk of infection with Leishmania infantum via transmission by sandflies (Phlebotomus perniciosus) for up to 3 weeks. The effect is indirect due to product’s activity against the vector.
Safety features: No
Marketing authorization holder: Elanco Animal Health GmbH 
Marketing authorization number: 1173 
Marketing authorization issued on: February 6, 2004 
Marketing authorization expires on: Unlimited 
Marketing authorization procedure type: National 
Assessment report:   
Package code Name of medicinal product Dosage form Package Legal status Reimbursements Reference price Last imported PƤritolumaa Additional information
1136720  Advantix  spot-on solution  200mg +40mg 0.4ml 0.4ml 1TK  OTC      22.05.2024     
1136731  Advantix  spot-on solution  200mg +40mg 0.4ml 0.4ml 2TK  OTC           
1136742  Advantix  spot-on solution  200mg +40mg 0.4ml 0.4ml 3TK  OTC           
1136753  Advantix  spot-on solution  200mg +40mg 0.4ml 0.4ml 4TK  OTC      24.04.2024     
1136764  Advantix  spot-on solution  200mg +40mg 0.4ml 0.4ml 6TK  OTC           
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription

You can download Acrobat Reader fromhere